ActivX Biosciences figures that the more you know about protein kinases, the easier it will be to inhibit them. That's the basis of its main product: a platform to profile protein kinases -- enzymes that regulate cell's signaling pathways. Its KiNativ platform has been launched for use by pharmaceutical and biotechnology companies as they develop the kinase inhibitors expected to make drug breakthroughs. The company also has its own pipeline of drug candidates in development, including one in trials for the treatment of Type-2 diabetes. Japanese drugmaker Kyorin Pharmaceutical, with whom ActivX had collaborated since 2002, bought the company in 2005 for $21 million.

Emisphere Technologies, Inc. company was founded in 1985. It was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. The company is headquartered in Cedar Knolls, New Jersey. Emisphere Technologies, Inc., a biopharmaceutical company, focuses on the delivery of therapeutic molecules and pharmaceutical compounds using its ‘eligen’ technology. The eligen technology could be applied to the oral route of administration, as well as the other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal, or transdermal. The company’s product pipeline includes Oral Salmon Calcitonin, which is in Phase III clinical trials for the treatment of osteoporosis and osteoarthritis; Oral Recombinant Parathyroid Hormone, which is in Phase I clinical trials for the treatment of osteoporosis; and Oral Heparin that is in Phase III clinical trials, as well as Oral Low Molecular Weight Heparin, which is in Phase I clinical trials for the treatment of cardiovascular diseases. Its products under development also comprise Oral Insulin, which is in Phase II clinical trials, as well as Oral Glucagon-Like Peptides, which is in Phase I clinical trials for the treatment of diabetes; Oral Recombinant Human Growth Hormone that is in Phase I clinical trials for the treatment of growth disorders; and Oral Acyclovir, an anti-viral compound that is in Phase I clinical trials. In addition, the company’s product pipeline consists of Oral PYY 3-36, which is in Phase I clinical trials for treating obesity; Oral Cromolyn Sodium that is in Phase I clinical trials for the treatment of asthma/allergies; and Oral Gallium, a preclinical stage product candidate, for oncology treatment. Emisphere Technologies has collaboration agreements with Novartis Pharma AG; Roche; and Genta, Inc.

Harlan was found in 1931 by Howard Harlan. Harlan Laboratories (formerly Harlan Sprague Dawley) is where scientists go when they need rats for the maze. Among other things, the research company produces laboratory animals and laboratory animal diets. The company is comprised of two operating groups. The Research Models group provides rodents and large animals, animal diets and bedding, and testing services to pharmaceutical and biotech companies, universities, and government agencies. The Contract Research Services division provides researchers with analytical chemistry services, toxicology services, and chemical and agrochemical registration.

ProMetic was founded in 1994. The scientists at ProMetic Life Sciences are meticulous about proteins. The biotech company develops protein technologies for pharmaceutical, diagnostic, and blood and plasma product development. ProMetic's Protein Technologies division licenses its technologies to companies around the globe, who then make their own products. The company's Therapeutics division conducts proprietary drug development programs for blood disease and cancer therapeutics. The company has collaborative agreements with pharmaceutical companies and health organizations such as Abraxis BioScience, Merck Serono, and The American Red Cross.

Ark Therapeutics is loading its boat with therapies that target cancer and vascular disease. The biotech company has one product on the market in the UK and the US -- Kerraboot, a wound dressing that treats chronic leg and foot ulcers. Lead candidate Cerepro has shown promise in extending the lives of brain tumor patients. And it has two other clinical-stage candidates that may treat cancer-related muscle wasting and prevent blood vessels from blocking after vascular graft surgery. The firm develops and markets its own products in key markets, such as Europe and the US; it largely develops drugs for indications where it has a good chance of getting the regulatory privileges of Fast Track or Orphan Drug status.

Spectrum Pharmaceuticals, Inc. operates as a commercial-stage biotechnology company with a primary focus in oncology market. The company focuses on acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products. Its marketed products include ZEVALIN, a form of cancer therapy called radioimmunotherapy for the treatment of non-Hodgkin's Lymphoma; and FUSILEV, which is indicated after high-dose methotrexate therapy in patients with osteosarcoma. The company also develops apaziquone for the treatment of non-muscle invasive bladder cancer. Its phase II products comprise Ozarelix, a drug being investigated for benign prostatic hypertrophy, a non-cancerous enlargement of the prostate; and Ortataxel, a third-generation taxane. In addition, Spectrum Pharmaceuticals, Inc. has exclusive worldwide rights to Renazorb, Renalan, and related compounds. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Irvine, California.

Minster Pharmaceuticals plc, through its subsidiary, Minster Research Limited, develops pharmaceutical compounds for the treatment of neurological and psychiatric conditions in the United Kingdom. Its products pipeline comprises Tonabersat, which is in Phase IIb clinical trial for the prevention and treatment of migraine; and Sabcomeline, a Phase IIa clinical trial product for the management of cognitive decline and negative symptoms in schizophrenia. The company is based in Saffron Walden, the United Kingdom.

Intercytex Limited company is developing cell-based treatments for skin and hair regeneration. Its ICX-TRC product candidate is injected just beneath the scalp to encourage new hair follicles to form. If the candidate wins approval in the US, Intercytex has lined up Bosley Medical Institute, a firm that manages hair transplant clinics across the US, to help distribute its regeneration product. Another product candidate, SHEF-1, could treat age-related macular degeneration. Its ICX-RHY launched in the UK in 2008 under the name Valvelta, as a cosmetic facial rejuvenation product injected transdermally to smoothe out wrinkles.

Biotie is a drug discovery and development company focused on central nervous system and inflammatory diseases. It has a broad range of innovative small molecule and biological drug candidates at different stages of clinical and pre-clinical development. Biotie’s products address diseases with high unmet medical need and significant market potential, including addiction and psychotic disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S. The commercial value of the pipeline has been demonstrated through existing alliances with top-tier global pharmaceutical companies such as Lundbeck, Roche and Pfizer. Biotie has operations in Turku, Finland and Radebeul, Germany.

Novartis Corporation has what the doctor ordered. As the North American headquarters of Switzerland-based Novartis AG, the unit handles administration, sales, and marketing for a vast product line of prescription drugs, consumer health products, vaccines, and veterinary products. But wait, there is more! Novartis Corporation also oversees the Novartis Institutes for Biomedical Research, which is headquartered in the US. Novartis Corporation headlines dozens of US business units including CIBA Vision, Novartis Pharmaceuticals, and the US operations of its Sandoz generics business.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.